Nightstar gene therapy used in first US patient with X-linked retinitis pigmentosa

A patient at Bascom Palmer Eye Institute has become the first in the United States to receive an innovative gene therapy treatment for X-linked retinitis pigmentosa as part of a Nightstar Therapeutics clinical trial, according to a press release.
Julio Adorno Nieves, 23, of Puerto Rico, is the 16th patient worldwide to receive the treatment. The treatment was delivered to his left eye in a 99-minute surgery by Janet L. Davis, MD, professor of ophthalmology and holder of the Leach Chair in Ophthalmology, and Ninel Gregori, MD, associate professor of (Read more...)

Full Story →

Nightstar gene therapy used in first US patient with X-linked retinitis pigmentosa

A patient at Bascom Palmer Eye Institute has become the first in the United States to receive an innovative gene therapy treatment for X-linked retinitis pigmentosa as part of a Nightstar Therapeutics clinical trial, according to a press release.
Julio Adorno Nieves, 23, of Puerto Rico, is the 16th patient worldwide to receive the treatment. The treatment was delivered to his left eye in a 99-minute surgery by Janet L. Davis, MD, professor of ophthalmology and holder of the Leach Chair in Ophthalmology, and Ninel Gregori, MD, associate professor of (Read more...)

Full Story →